Heart transplant patient warns of 'ghost approval' gap that leaves life-saving drugs out of reach

A heart transplant recipient and patient advocate describes how the medication everolimus (Zortress) is essential to prevent organ rejection, not an optional treatment.

The author coins the term "ghost approval" to describe situations where insurance formally approves a drug but practical barriers-such as prior authorization, specialty pharmacy routing, high‑cost tiers, or the lack of an FDA label for the specific indication-still block the patient from obtaining it.

This disconnect between clinical prescribing and insurance or regulatory processes leaves patients vulnerable and underscores the need for policy changes that ensure approved coverage translates into real access.